| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NGNE | Common Stock | Purchase | $517K | +20.7K | +1.24% | $24.91 | 1.69M | Nov 26, 2024 | By Samsara BioCapital, L.P. | F1, F2 |
| transaction | NGNE | Common Stock | Purchase | $281K | +10.8K | +0.64% | $26.01 | 1.7M | Nov 26, 2024 | By Samsara BioCapital, L.P. | F2, F3 |
| transaction | NGNE | Common Stock | Purchase | $407K | +15.2K | +0.9% | $26.73 | 1.72M | Nov 26, 2024 | By Samsara BioCapital, L.P. | F2, F4 |
| transaction | NGNE | Common Stock | Purchase | $55K | +2K | +0.12% | $27.50 | 1.72M | Nov 26, 2024 | By Samsara BioCapital, L.P. | F2, F5 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. |
| F2 | Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
| F3 | The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. |